Related to Human Genome Sciences Earns $75M from Novartis as HCV Drug Gets Prepared for Regulatory Submissions

• Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results
  
• Adimab Inks Separate Discovery Deals with Eli Lilly, Genentech, and HGS
  
• Novartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use
  
• FDA Green-Lights HGS and GSK’s Systemic Lupus Erythematosus Drug Benlysta
  
• Second Phase III Study Shows Incyte and Novartis Drug Reduces Spleen Size in Myelofibrosis
  
• Human Genome Sciences Pays FivePrime $50M Up Front for Phase I Anticancer Agent
  
• Novartis Pays GW Pharm $5M Up Front for Sativex Rights in Multiple Territories
  
• Novartis and Vectura Confirm Positive Data from First Phase III Study with COPD Drug
  
• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• 4-Antibody Signs Discovery and Development Deal with Human Genome Sciences
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• Novartis Pays Genmab $2M to Tap into Bispecific Antibody Technology
  
• BMS, Vertex Plan Phase II Studies of Hep C Combo Therapy
  
• Roche, Ascletis to Develop HCV Drug in China
  
• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Idenix Restructures to Concentrate on HCV and HIV Programs
  
• Novartis Negotiates Rights to Debiopharm’s Mid-Stage HCV Candidate
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• Novartis Pulls MAA for HCV Therapy Developed with Human Genome Sciences
  
• Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns